Home FOR AUTHORS Neoplasma 2021 Neoplasma Vol.68, No.5, p.1072–1078, 2021

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.68, No.5, p.1072–1078, 2021

Title: Features and impacts on the prognosis of gene mutations in patients with acute myeloid leukemia
Author: Ming Wu, Zi-Wen Guo, Gui-Nian Huang, Yong-Bin Ye

Abstract: To explore features and impacts on the prognosis of common gene mutations in acute myeloid leukemia (AML), we assessed mutated status as well as variant allele frequency (VAF) of 24 genes in 81 AML patients by next-generation sequencing (NGS) technology. Eighty-six percentages of patients showed at least one mutation. Mutation in BCOR was associated with lower complete remission (CR) rate, whereas double mutation in CEBPA was associated with a favorable odds ratio for CR achievement. TP53 mutation was associated with inferior overall survival (OS) in univariate analysis. Multivariate analysis confirmed the negative effect of adverse cytogenetic abnormalities on survival. Mutation in RUNX1 and ZRSR2 had negative impacts on OS in patients with wild-type TP53. VAF of SRSF2 mutation was observed negatively correlated with OS. In conclusion, our study suggested that mutations in BCOR and spliceosomes might predict worse outcomes, and VAF of gene mutations may play a crucial role in outcomes of AML patients.

Keywords: acute myeloid leukemia; next-generation sequencing; gene mutation; variant allele frequency
Published online: 17-May-2021
Year: 2021, Volume: 68, Issue: 5 Page From: 1072, Page To: 1078
doi:10.4149/neo_2021_201230N1426
Price: 14.70 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.